Showing posts with label asthma.. Show all posts
Showing posts with label asthma.. Show all posts

Fossil fuel combustion endangers children's health in two significant ways: A scientist reviews the evidence

Writing in a commentary in Environmental Health Perspectives, Frederica Perera, director of the Columbia Center for Children's Environmental Health (CCCEH), identifies fossil fuel combustion and associated air pollution and carbon dioxide (CO2) as the root cause of much of the ill health of children today. Because of their inherent biological vulnerability, children now bear a disproportionate burden of disease from both pollution and climate change.

Among the conclusions: by reducing air pollution we will see fewer babies born at low birth weight, and fewer children suffering from asthma and neurodevelopmental problems such as lower IQ and ADHD. Lowered emissions of CO2 and mitigation of climate change will reduce the number of children dying as a result of floods and drought, and fewer children will suffer from heat stress, malnutrition, infectious disease, respiratory illness, and mental illness from displacement, social, and political instability.


In utero Exposure to β-2-Adrenergic Receptor Agonist Drugs and Risk for Autism Spectrum Disorders. - PubMed - NCBI

The purpose of this study was to investigate associations between use of β-2-adrenergic receptor (B2AR) agonist drugs during pregnancy and risk for autism spectrum disorders (ASD).

METHODS:

A case-control study was conducted by using Denmark's health and population registers. Among children born between 1997 and 2006, 5200 cases with ASD admission diagnoses and 52 000 controls without ASD were identified and individually matched on month and year of birth. Conditional logistic regression models were used to estimate odds ratios (OR) and confidence intervals (CI) for any B2AR agonist exposure during pregnancy, preconception, and by trimester.

RESULTS:

In total, 3.7% of cases and 2.9% of controls were exposed to B2ARs during pregnancy. Use of B2ARs during pregnancy was associated with increased risk of ASD, even after adjustment for maternal asthma and other covariates (OR: 1.3, 95% CI: 1.1-1.5). The elevated risk was observed with use of B2AR during preconception (OR: 1.3, 95% CI: 1.0-1.6), first trimester (OR: 1.3, 95% CI: 1.1-1.5), second trimester (OR: 1.5, 95% CI: 1.1-1.7), and the third trimester (OR: 1.4, 95% CI: 1.1-1.7). There was some evidence that longer B2AR within-pregnancy use was associated with the increased risk.

CONCLUSIONS:

B2AR agonist exposure during pregnancy may be associated with an increased risk for ASD. If the effect is real, any intervention must be balanced against benefits of indicated medication use by pregnant women.